Ranolazine, the first in a new class of antianginal agents called the partial fatty acid oxidation (pFOX) inhibitors, improves exercise performance and reduces angina frequency in patients who still have symptoms despite treatment with other antianginal medications, according to Bernard Chaitman, ...